loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations
Open ICICI 3-in-1 Account

Anupam Rasayan India Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Anupam Rasayan India Ltd. 14 Aug 2026 12:06 PM
Result PDF

Q1FY27 Quarterly Result Announced for Anupam Rasayan India Ltd.

Specialty Chemicals company Anupam Rasayan India announced Q1FY27 results

Consolidated Financial Highlights:

  • Revenue from Operations for Q1FY27 was Rs 6,549.80 million, representing a YoY increase of 34.82% from Rs 4,858.27 million in Q1FY26 and a QoQ growth of 3.02% from Rs 6,357.83 million in Q4FY26.
  • Total Revenue stood at Rs 6,675.45 million in Q1FY27, up 36.03% YoY compared to Rs 4,907.39 million in Q1FY26 and 4.44% higher on a QoQ basis from Rs 6,391.52 million in Q4FY26.
  • Profit Before Tax (PBT) reached Rs 696.81 million in Q1FY27, showing a YoY growth of 10.87% from Rs 628.50 million in Q1FY26 and a QoQ increase of 24.28% from Rs 560.68 million in Q4FY26.
  • Profit after tax for the Period was Rs 512.15 million in Q1FY27, up 5.69% YoY from Rs 484.58 million in Q1FY26, but decreased by 8.54% QoQ from Rs 559.96 million in Q4FY26.
  • Basic Earnings Per Equity Share (EPS) for Q1FY27 was Rs 3.39 compared to Rs 3.10 in Q1FY26 and Rs 3.75 in Q4FY26.

Standalone Financial Highlights:

  • Revenue from Operations for Q1FY27 was Rs 3,288.05 million, a YoY growth of 4.15% from Rs 3,156.94 million in Q1FY26 and a QoQ decline of 11.27% from Rs 3,705.79 million in Q4FY26.
  • Total Revenue for Q1FY27 stood at Rs 3,348.88 million, up 4.48% YoY from Rs 3,205.20 million in Q1FY26 and down 10.23% QoQ compared to Rs 3,730.65 million in Q4FY26.
  • Profit Before Tax was Rs 416.98 million in Q1FY27, registering a YoY increase of 7.13% from Rs 389.21 million in Q1FY26 and a QoQ growth of 20.25% from Rs 346.75 million in Q4FY26.
  • Profit after tax for the Period was Rs 320.06 million in Q1FY27, rising 7.79% YoY from Rs 296.94 million in Q1FY26, while declining by 24.48% QoQ from Rs 423.84 million in Q4FY26.
  • Basic Earnings Per Equity Share (EPS) for Q1FY27 stood at Rs 2.81 as against Rs 2.70 in Q1FY26 and Rs 3.73 in Q4FY26.

Business Highlights:

  • Segment Performance: The company is primarily engaged in the business of custom synthesis and manufacturing of specialty chemicals, which is recognized by the management as the sole business segment.
  • Key Appointments: The Board has approved the appointment of Mr. Ravi Desai as Chief Operating Officer of the company with effect from August 14, 2026.
  • Corporate Developments: Monitchem Kansas S.a.r.l, a step-down subsidiary, was liquidated with effect from June 30, 2026.

Anand Desai, Managing Director, Anupam Rasayan India, said, "We are pleased to begin fiscal year 2027 on a strong note. Consolidated Revenue for the quarter grew 36% year-on-year, a result that reflects sustained momentum across our businesses and continued execution of our strategy to build a globally integrated specialty chemicals and CDMO platform.

We would like to highlight an important technological milestone achieved during the quarter. We became the first company in the world to commercialize Ethyl Trifluoroacetate, or ETFA, using flow chemistry - a significant advancement that further strengthens our capabilities in complex fluorination.

We also signed a Letter of Intent with BASQUEVOLT, S.A. for the potential long-term supply of a specialty chemical product. This represents a revenue opportunity of approximately US$300 million spread over a period of ten years.

Turning to our pharmaceutical business, the proposed acquisition of Bliss GVS Pharma continues to progress as planned, following the signing of the definitive agreement. Upon completion, we expect this transaction to strengthen our pharmaceutical platform through synergies across CDMO capabilities, product development, customer relationships, and access to regulated markets.

Looking ahead, we remain confident in our growth prospects. This confidence is supported by a strong product pipeline, expanding opportunities across our Performance Materials and Pharmaceuticals segments, deeper customer engagement, and continued investment in technology and innovation. Together, these initiatives position us well to deliver sustainable growth and long-term value creation."

Result PDF

Result PDF

Specialty Chemicals company Anupam Rasayan India announced Q4FY26 & FY26 results

Consolidated Financial Highlights:

  • Revenue from Operations: Stood at Rs 6,357.83 million in Q4FY26, reflecting a YoY growth of 27.12% from Rs 5,001.58 million in Q4FY25, and a QoQ increase of 24.07% from Rs 5,124.47 million in Q3FY26. For FY26, revenue reached Rs 23,654.55 million, growing 64.61% YoY from Rs 14,369.74 million in FY25.
  • Total Revenue: Reported at Rs 6,391.52 million for Q4FY26, marking a YoY rise of 26.39% against Rs 5,056.96 million in Q4FY25, and a QoQ growth of 24.22% from Rs 5,145.47 million in Q3FY26. Annual total revenue for FY26 stood at Rs 23,836.29 million, reflecting a 64.57% YoY increase from Rs 14,484.51 million in FY25.
  • Profit after Tax (Net Profit): For Q4FY26, net profit was Rs 559.96 million, demonstrating a decline of 11.02% YoY from Rs 629.28 million in Q4FY25, and a drop of 7.59% QoQ from Rs 605.93 million in Q3FY26. For FY26, profit after tax grew 38.90% YoY to Rs 2,221.99 million compared to Rs 1,599.72 million in FY25.
  • Net Profit Attributable to Owners: Stood at Rs 426.50 million in Q4FY26, down from Rs 445.67 million in Q4FY25 and Rs 490.41 million in Q3FY26. For FY26, it increased significantly to Rs 1,701.21 million from Rs 933.49 million in FY25.

Standalone Financial Highlights:

  • Revenue from Operations: Reached Rs 3,705.79 million in Q4FY26, showing a YoY growth of 12.07% from Rs 3,306.73 million in Q4FY25, but a QoQ decline of 7.67% from Rs 4,013.67 million in Q3FY26. Annual revenue for FY26 stood at Rs 16,755.67 million, up 87.03% YoY from Rs 8,958.99 million in FY25.
  • Total Revenue: For Q4FY26, total revenue was Rs 3,730.65 million, an increase of 11.03% YoY from Rs 3,359.94 million in Q4FY25, but a QoQ drop of 8.18% from Rs 4,063.20 million in Q3FY26. Annual total revenue for FY26 reached Rs 16,955.30 million, growing 86.48% YoY from Rs 9,092.49 million in FY25.
  • Profit after Tax (Net Profit): Stood at Rs 423.84 million in Q4FY26, up 11.27% YoY from Rs 380.91 million in Q4FY25, but down 11.55% QoQ from Rs 479.19 million in Q3FY26. For FY26, profit after tax grew substantially by 122.08% YoY to Rs 1,613.96 million compared to Rs 726.74 million in FY25.

Business Highlights:

  • Segment Performance: The Company is primarily engaged in the custom synthesis and manufacturing of specialty chemicals. The management and the Chief Operating Decision Maker (CODM) recognize this as the sole business segment; hence, separate segment-wise information is not required.
  • Major Acquisition (Bliss GVS Pharma): The Board approved the acquisition, directly or indirectly, of equity shares carrying voting rights of up to 74.20% of the total paid-up share capital and control of Bliss GVS Pharma Limited.
  • Consummation of Jayhawk Acquisition: The Company successfully consummated the acquisition of a 100% equity stake in Jayhawk Fine Chemicals Corporation (a U.S.-based specialty chemical company part of the CABB group) effective February 27, 2026. The purchase consideration was ~USD 150 million, executed through its wholly-owned subsidiary, Doriath S.à r.l.
  • Goodwill on Acquisition: The Group recognized goodwill of Rs 5,402.56 million related to the acquisition of JayHawk Fine Chemicals Corporation on a provisional basis, pending the finalization of the purchase price allocation.
  • Fundraising: The Board approved the raising of funds up to Rs 160 crore by issuing 16,000 Secured, Rated, Unlisted, Redeemable, Non-Convertible Debentures (NCDs) having a face value of Rs 1 lakh each, on a private placement basis.
  • Dividend: The Board recommended a Final Dividend of Rs 1.5/- per Equity Share (15% of face value of Rs 10/- each) for the financial year 2025-26, subject to shareholder approval.
  • Key Personnel Changes: The Board accepted the resignation of Mr. Vishal Thakkar from the post of Deputy Chief Financial Officer and Key Managerial Personnel of the Company with immediate effect.
  • Tax Recomputation: Deferred tax assets and liabilities were recomputed by the Parent company based on the enactment of Finance Bill 2026, and the resulting impact of the remeasurement has been recognized in the Statement of Profit and Loss.

Anand Desai, Managing Director, Anupam Rasayan India, said: “We are pleased to share that FY26 has been a landmark year for Anupam Rasayan, marked by strong operational execution, strategic expansion, and continued progress toward building a globally integrated specialty chemicals and CDMO platform. During the year, the Company achieved its highest-ever annual sales and operating cash flow performance, reflecting robust business momentum, operational efficiency, and strong cash generation. Growth was driven by commercialization of new products, addition of new multinational customers, and expanding engagements across key business verticals.

We continue to strengthen our presence in niche and complex chemistries where technical expertise and long qualification cycles create strong entry barriers and sustainable growth opportunities.

A key strategic milestone during the year was the successful acquisition of Jayhawk Fine Chemicals in the United States. Jayhawk delivered strong pro forma revenue of USD 95 million, reinforcing the strategic value of the acquisition and strengthening our global manufacturing footprint, advanced chemistry capabilities, and integrated CDMO platform. The acquisition also enhances our access to regulated markets and innovator customers across North America.

Additionally, we have signed a definitive agreement to acquire Bliss GVS Pharma which will further strengthen our pharmaceutical value chain capabilities and is expected to create meaningful synergies across CDMO capabilities, product portfolio, and customer relationships.

Looking ahead, we remain well-positioned for the next phase of growth, supported by increasing contribution from Performance Materials and the Pharma segment, a strong product pipeline, and expanding global customer engagements.”

Result PDF

Specialty Chemicals company Anupam Rasayan India announced Q3FY26 results

  • Total revenue for Q3FY26 was at Rs 5,145 million as compared to Rs 3,866 million in Q3FY25; up 33% YoY.
  • EBITDA (incl. other income) was at Rs 1,296 million in Q3FY26 as compared to Rs 1,208 million in Q3FY25, up 7% and this would translate into 25.20% EBITDA margin in this quarter.
  • Profit After Tax was at Rs 606 million in Q3FY26 as compared to Rs 542 million in Q3FY25; up 12% YoY.

Anand Desai, Managing Director, Anupam Rasayan, said: “I am pleased to share that for 9MFY26, we delivered consolidated revenue of Rs 17,297 million with EBITDA of Rs 4,024 million, reflecting strong YoY growth. For Q3FY26, revenue stood at Rs 5,124 million with EBITDA of Rs 1,296 million, demonstrating continued growth momentum.

A significant strategic development during the period has been the signing of a definitive agreement to acquire Jayhawk Fine Chemicals Corporation in the United States. This acquisition strengthens our global footprint, enhances our capabilities in advanced custom synthesis, and deepens our access to regulated markets and innovator customers in North America. It represents an important step in our journey toward becoming a global specialty chemical platform."

Result PDF

Specialty Chemicals company Anupam Rasayan India announced Q2FY26 results

  • Total revenue for Q2FY26 was at Rs 7,392 million as compared to Rs 2,959 million in Q2FY25; up 149% YoY.
  • EBITDA (incl. other income) was at Rs 1,436 million in Q2FY26 as compared to Rs 824 million in Q2FY25, up 74% and this would translate into 19% EBITDA margin in this quarter.
  • Profit After Tax was at Rs 572 million in Q2FY26 as compared to Rs 306 million in Q2FY25; up 87% YoY.

Anand Desai, Managing Director, Anupam Rasayan, said, “I am delighted to share that Q2FY26 has been one of the best quarters for our company. We delivered a stellar performance with consolidated revenue from operations of Rs 739 crore, reflecting exceptional growth of 149% YoY and 51% sequentially. For H1FY26, consolidated revenue stood at Rs 1,229 crore, registering a robust 122% YoY growth.

I am pleased to highlight that within just six months of this financial year, we have already surpassed the total revenue of FY25, demonstrating the resilience of our business model, strong customer relationships, and operational excellence. Our subsidiary, Tanfac Industries, also delivered a strong performance during H1FY26, reporting revenue of Rs 345 crore, marking a 67% YoY growth.”

Result PDF

Specialty Chemicals company Anupam Rasayan India announced Q1FY26 results

  • Total revenue for Q1FY26 was at Rs 4,907 million as compared to Rs 2,603 million in Q1FY25; up 89% YoY.
  • EBITDA (incl. other income) was at Rs 1,292 million in Q1FY26 as compared to Rs 592 million in Q1FY25, up 118% and this would translate into 26% EBITDA margin in this quarter.
  • Profit After Tax was at Rs 485 million in Q1FY26 as compared to Rs 122 million in Q1FY25; up 297% YoY.

Anand Desai, Managing Director, Anupam Rasayan, said: “During Q1FY26, consolidated revenue stood at Rs 491 crore, registering a robust growth of 89% year-on-year. We strongly believe that the sectoral trends are in our favour, and we are witnessing a clear resurgence in growth. Our pharma and polymer businesses are performing well, coupled with a recovery in the Agrochemical segment.

The USA and Japan markets have shown encouraging trends for Anupam Rasayan. During Q1FY26, total exports accounted for 58% of the total revenue from operations.

With the two new agreements signed with Japanese and US-based multinational companies, our order book now stands at Rs 14,646 crore, reflecting the strong growth momentum in our business.”

Result PDF

Specialty Chemicals company Anupam Rasayan India announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Total revenue for Q4FY25 was at Rs 5,057 million as compared to Rs 4,130 million in Q4FY24; up 22% YoY.
  • EBITDA (incl. other income) was at Rs 1,500 million in Q4FY25 as compared to Rs 1,047 million in Q4FY24, up 43% and this would translate into 30% EBITDA margin in this quarter.
  • Profit After Tax was at Rs 629 million in Q4FY25 as compared to Rs 405 million in Q4FY24; up 56% YoY.

FY25 Financial Highlights:

  • Total revenue for FY25 was at Rs 14,485 million as compared to Rs 15,053 million in FY24; down 4% YoY.
  • EBITDA (incl. other income) was at Rs 4,123 million in FY25 as compared to Rs 4,109 million in FY24, this would translate into 28% EBITDA margin in FY25.
  • Profit After Tax was at Rs 1,600 million in FY25 as compared to Rs 1,674 million in FY24.

Speaking on the performance, Anand Desai, Managing Director, Anupam Rasayan commented, “Consolidated revenue for the quarter Q4FY25 stood at Rs 506 crores registering a growth of 22% YoY and 31% QoQ. Consolidated revenue for the full year FY25 stood at Rs 1,448 crores registering a degrowth of 4% YoY. This performance was supported by growth in pharma and polymer coupled with strong performance from Tanfac. Margins have remained consistent this quarter, reflecting our focus on operational efficiency and a favourable product mix.

While H1 FY25 was subdued due to weak macro conditions, I am pleased to share that H2 has shown clear signs of recovery — particularly in Q4 FY25 where we have seen meaningful improvement with sales increasing both year-on-year and sequentially. We remain confident in our ability to return to the historical growth rates achieved prior to the recent slowdown.”

Result PDF

Specialty Chemicals company Anupam Rasayan India announced Q3FY25 results

  • Total revenue for Q3FY25 was at Rs 3,866 million as compared to Rs 2,979 million in Q3FY24; up 30% YoY.
  • EBITDA (incl. other income) was at Rs 1,208 million in Q3FY25 as compared to Rs 815 million in Q3FY24, up 48% and this would translate into 31% EBITDA margin in this quarter.
  • Profit After Tax was at Rs 542 million in Q3FY25 as compared to Rs 260 million in Q3FY24; up 108% YoY.

Anand Desai, Managing Director, Anupam Rasayan commented, “Our Pharma and Polymer segments, which have emerged as key growth drivers, continue to strengthen their contribution to our revenue. Both the segments coupled with strong performance of Tanfac led to significant growth this quarter, fueling a robust 31% QoQ revenue growth in Q3FY25 on a consolidated basis. For the full year, we expect them to play a substantial role in overall revenue, with this upward trend projected to continue into FY26. Additionally, the Agrochemical segment has shown signs of recovery, particularly in the European market."

"With strong demand momentum and expected off-take from our customers, we anticipate regaining our growth trajectory in the next financial year, aiming for a 30-35% revenue increase in FY26.

Result PDF

Specialty Chemicals company Anupam Rasayan India announced H1FY25 & Q2FY25 results

Q2FY25 Financial Highlights:

  • Total revenue for Q2FY25 was at Rs 2,959 million as compared to Rs 3,956 million in Q2FY24.
  • EBITDA (incl. other income) was at Rs 824 million in Q2FY25 as compared to Rs 1,109 million in Q2FY24, this would translate into 28% EBITDA margin in this quarter.
  • Profit After Tax was at Rs 306 million in Q2FY25 as compared to Rs 487 million in Q2FY24.

H1FY25 Financial Highlights:

  • Total revenue for H1FY25 was at Rs 5,562 million as compared to Rs 7,944 million in H1FY24.
  • EBITDA (incl. other income) was at Rs 1,416 million in H1FY25 as compared to Rs 2,247 million in H1FY24, this would translate into 25% EBITDA margin in H1FY25.
  • Profit After Tax was at Rs 428 million in H1FY25 as compared to Rs 1,009 million in H1FY24.

Anand Desai, Managing Director, Anupam Rasayan said: "In Q2FY25, we were nearing the end of a demand slump in the Agro segment, and we are now seeing a good recovery. The Pharma and Polymer segments, meanwhile, have been showing robust growth, fuelled by the launch of over 17 new molecules in FY24 and 3 additional molecules in H1FY25. As these products gain traction, we expect their contribution to grow. Additionally, the planned launch of more than 3 new molecules in the coming months should further accelerate growth in these areas.

Our consolidated operating revenue for the quarter was Rs 294 crores, representing a QoQ growth of 14%, with a stable EBITDA margin of 28% in Q2FY25. We anticipate revenue to normalize as volumes increase in the latter half of the year. With the new capacity, scaling of recently launched fluorinated molecules, and signed LOIs and contracts, we are optimistic about strong growth over the medium term."

Result PDF

Speciality Chemicals company Anupam Rasayan India announced consolidated Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Total revenue for Q4FY24 was at Rs 4,130 million as compared to Rs 5,042 million in Q4FY23; down 18% YoY.
  • EBITDA (incl. other income) was at Rs 1,047 million in Q4FY24 as compared to Rs 1,416 million in Q4FY23 – degrowth of 26% YoY, this would translate into 25% EBITDA margin in this quarter.
  • Profit After Tax was at Rs 405 million in Q4FY24 as compared to Rs 726 million in Q4FY23 - degrowth of 44% YoY. 

FY24 Financial Highlights:

  • Total revenue for FY24 was at Rs 15,053 million as compared to Rs 16,105 million in FY23; down 7% YoY.
  • EBITDA (incl. other income) was at Rs 4,109 million as compared to Rs 4,399 million in FY23 – degrowth of 7.0% YoY, this would translate into 27% EBITDA margin.
  • Profit After Tax was at Rs 1,674 million as compared to Rs 2,168 million in FY23 - degrowth of 23% YoY. 

Speaking on the performance, Anand Desai, Managing Director, Anupam Rasayan commented, “Indian chemical industry including spec chem industry has faced significant headwinds during the last year. However, despite the de-growth in the top-line, we have been able to sustain our profitability and maintain margins at 27% levels on a full year consolidated basis. During the year, the Agro chemical industry in particular faced challenges, however our past sustained efforts in expanding our pharma and polymer portfolio have started yielding results leading to pharma contributing over 9% of revenue in FY24, up from 4% last year. We expect pharma and polymer segment each to further increase their revenue share in double digits by next year.

In FY2024, we have focused on expanding our customers, products and end market applications. We have added 17 new molecules, 4 new MNCs including 2 Japanese majors and expanded contribution from polymer and pharma which going forward will lead to balanced product portfolio from end market perspective.

We believe that headwinds in the industry may continue for the next two quarters. However, financial year 2025 will be a year of growth for us with our major focus on polymer and pharmaceutical space.”

Result PDF

Agrochemicals company Anupam Rasayan announced consolidated 9MFY24 results:

  • Total revenue for 9MFY24 was at Rs 10,923 million compared to Rs 11,062 million in 9MFY23, representing a decrease of 1.26% YoY.
  • EBITDA (including other income) was at Rs 3,062 million in 9MFY24 compared to Rs 2,984 million in 9MFY23, reflecting a growth of 2.62% YoY. This translates into a 28.03% EBITDA margin.
  • Profit After Tax was at Rs 1,270 million in 9MFY24 compared to Rs 1,442 million in 9MFY23.

Commenting on the performance, Anand Desai, Managing Director of Anupam Rasayan, remarked, “The chemical industry continues to face headwinds impacting our performance for the quarter. This, coupled with clients off-taking minimum required quantities to manage their year-end working capital, has led to a degrowth in our revenues for the quarter. Even during such difficult times, we have been able to maintain our margins steady at 28% for the 9MFY24 on a consolidated basis.

I am happy to inform you that, during the quarter, we signed a Letter of Intent worth $61 million i.e., Rs 507 crore for the next 9 years with one of the leading Japanese Chemical companies to supply new age polymer intermediate. I firmly believe that our Japan business will see strong growth in the coming years and will likely become a major business centre for Anupam.

As a next step forward in our sustainability journey, the company has decided to invest Rs 59 crore towards setting up a 9.6 MW hybrid (Wind plus Solar) power plant. Post completion of this capex, 65% of the company’s electricity consumption will be from green energy.

Overall, I believe FY24 will be a challenging year for the industry but with a resilient and robust business model like ours, I am confident that FY25 will be a year of demand resurgence and strong growth.”

 

Result PDF

Trending News

IQVIA: Indian Pharma Market grows 13% YoY to ₹24,827 cr in August; Chronic segment surges 16%Show Code

As per IQVIA, Indian Pharma Market grew at 13% YoY to ₹ 24,827 crore in August 2026. On the MAT (trailing 12 months) basis, IPM witnessed a growth of 12.3% to ₹ 271,284 crore. 

Published on 11-Sep-2026 09:12

India CV Growth Outlook Hiked to 10-15% for FY27 as Q1 and August Sales Surge Past Estimates

According to media sources, India’s commercial vehicle (CV) industry has sharply upgraded its FY27 growth outlook after demand in the first five months significantly exceeded expectations. 

Published on 11-Sep-2026 09:11

UPI Merchant Levy of 40 bps in the Works; Issuing Banks to Get Max Share; Free for Small Retailers

As per media sources, a ~40 bps MDR on select UPI merchant transactions is being worked out, with issuing banks expected to receive the largest share

Published on 11-Sep-2026 09:10

HDFC Bank wins all 7 Credit Suisse AT1 bond cases in Bahrain

As per media sources, HDFC Bank has won all seven cases filed against it in Bahrain by investors in Credit Suisse AT1 bonds, providing relief from allegations of mis-selling. 

Published on 11-Sep-2026 09:09

Neogen Chemicals launches QIP with ₹2,189.73/share floor price

Neogen Chemicals has invited bids from eligible qualified institutional buyers under its QIP, with the floor price set at ₹2,189.73/share. 

Published on 11-Sep-2026 09:08

KIMS Hospitals to operate 183-bed Trust Hospital in Kakinada

KIMS Hospitals has entered into an Operation and Management (O&M) Agreement with Sarvottam Health Care Pvt Ltd to become the exclusive operator of Trust Multispeciality Hospital in Kakinada, Andhra Pradesh

Published on 11-Sep-2026 09:07

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app